Evaluating the safety and efficacy of oocyte and embryo vitrification for fertility preservation - Evaluating the safety and efficacy of oocyte and embryo vitrification for fertility preservation

Keio University0 sites43 target enrollmentSeptember 1, 2017

ConditionsCancer, Hematologic disease, Immune disorders

Overview

Phase: 未知
Intervention: Not specified
Conditions: Cancer, Hematologic disease, Immune disorders
Sponsor: Keio University
Enrollment: 43
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Gonadotoxic treatment resulted in fewer oocytes. Although anti-Mullerian hormone levels were lower in the post-gonadotoxic treatment group than in the pre-gonadotoxic treatment group, oocyte maturation rates were higher in the post-gonadotoxic treatment group than in the pre-gonadotoxic group.

Registry

who.int

Start Date

September 1, 2017

End Date

October 23, 2024

Last Updated

2 years ago

Study Type

Interventional

Sex

Female

Investigators

Sponsor

Keio University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. Freezing 1\) The patients who cannot realize or obtain informed consent. 2\) The patients judged to be inappropriate for the study by the physicians. 3\) The case to delay treatments because of fertility preservation. 2\. Fertilization, Embryo Transfer 1\) Unmarried patients. 2\) The patients who are more than 50 years old. 3\) The patients undergoing hysterectomies. 4\) The patients whose cancers, hematological diseases, or immune disorders have progressed at the time of embryo transfer.